Faculty

Institution

Unit

Venue

Marc M. Loriaux, M.D., Ph.D.

Associate Professor of Pathology & Laboratory Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Hematopathology

Department of Medicine

Division Of Hematology/Medical Oncology

School of Dentistry

Department of Pathology and Radiology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Marc M. Loriaux, M.d., Ph.d. is currently serving as a Biostatistics Shared Resources Associate Professor of Pathology & Laboratory Medicine at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Marc M. Loriaux, M.D., Ph.D.

Oregon Health & Science University

Associate Professor of Pathology & Laboratory Medicine

You can click a keyword to filter the displayed items

hematology leukemia pharmacology cancer research oncology hematological malignancies genetics medicinal research cell biology immunology cancer biology oncogenes tumor biology therapeutic targets cancer genetics cancer cells molecular cancer cell signaling myeloid neoplasia cancer genomics acute myeloid leukemia cytogenetics novel therapies cancer immunotherapy gene expression molecular diagnostics cellular therapy anti-cancer agents enzyme inhibition pharmacotherapy cancer treatment therapeutic efficacy cancer care genome biology bone marrow transplantation hemostasis lymphoid neoplasia vascular surgery medical genetics mixed-phenotype acute leukemia murine model cancer discovery protein science tumor targeting malignant blood disorders disease gene identification gene characterization molecular cell biology gene expression profiling tumor suppressors interventional radiology cytokines blood cells anticoagulants endovascular management endovascular techniques cell therapy drug targeting oncogenic agent cell regulation molecular regulation chronic lymphocytic leukemia hematologic malignancies mutagenesis chronic myeloid leukemia myeloproliferative neoplasms acute lymphoblastic leukemia tyrosine kinome potential therapeutic strategy drug resistant myeloma refractory multiple myeloma functional genomic landscape mutation-based resistance pan-bcr-abl inhibitor cellular viability b-cell malignancies

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Characterization of Murine Jak2 Sup V617F /Sup -Positive Myeloproliferative Disease. (2023)

Thomas G.P. BummCollin ElseaAmie S. CorbinMarc LoriauxDaniel SherbenouLisa WoodJutta DeiningerRichard T. SilverBrian J. DrukerMichael W.N. Deininger

genomicshematologygeneticsmyelopoiesismolecular biologygene characterizationcell biology

Data From the Colony-Stimulating Factor 3 Receptor T640N Mutation is Oncogenic, Sensitive to Jak Inhibition, and Mimics T618i. (2023)

Julia E. MaxsonSamuel B. LutyJason D. MacManimanJason C. PaikJason GotlibPeter GreenbergSwaleh BahamadiSamantha L. SavageMelissa L. AbelChristopher A. EideMarc M. LoriauxEmily A. StevensJeffrey W. Tyner

carcinogenesisreceptorspharmacologygeneticsmolecular biologyoncogenestumor biology

Data From Therapeutically Targetable Alk Mutations in Leukemia. (2023)

hematological malignanciesleukemiamyeloid neoplasiacancer researchsystems biologymolecular cancermolecular diagnosticsoncogenesmolecular medicine

Supplemental Figure 1 (Transformation Assays) and Supplemental Figure 2 (Colony Assays) From the Colony-Stimulating Factor 3 Receptor T640N Mutation is Oncogenic, Sensitive to Jak Inhibition, and Mimics T618i. (2023)

gene therapynovel therapiesinhibitory activityreceptor (biochemistry)transformation assaysreceptor tyrosine kinasesprotein sciencereporter gene assaycolony assaysmolecular physiologytumor biologyreceptorsgene expressionpharmacologygeneticsdrug discoverymolecular biologyoncogenesmedicinal researchcellular therapy

Supplemental Figure S1 From Therapeutically Targetable Alk Mutations in Leukemia. (2023)

hematological malignanciesleukemiacancer geneticsmyeloid neoplasiacancer researchmolecular cancertherapeutic targetsmolecular diagnosticsmolecular biologyoncogenescancer cellssupplemental figure s1pathologymolecular medicinecell biology

Supplementary Legends for Tables 1-4 and Figures 1-7 From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

Jeffrey W. TynerWayne F. YangArmand BankheadGuang FanLuke B. FletcherJade BryantJason M. GloverBill H. ChangStephen E. SpurgeonWilliam H. FlemingTibor KovacsovicsJason R. GotlibStephen T. OhMichael W. DeiningerChristian Michel ZwaanMonique L. Den BoerMarry M. van den Heuvel-EibrinkThomas O'HareBrian J. DrukerMarc M. Loriaux

immunologyleukemiapharmacologykinase pathway dependencecancer researchsupplementary legendsrapid inhibitor screeninggeneticsoncologymedicinal researchcancer biologyprimary human leukemias

Supplementary Methods and Materials From Characterization of Murine Jak2 Sup V617F /Sup -Positive Myeloproliferative Disease. (2023)

Thomas G.P. BummCollin ElseaAmie S. CorbinMarc LoriauxDaniel SherbenouLisa WoodJutta DeiningerRichard T. SilverBrian J. DrukerMichael W.N. Deininger

myelopoiesissupplementary methodshematologycell biology

Supplementary Table 2 From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

immunologyleukemiapharmacologytreatment developmentkinase pathway dependencecancer researchtreatment effectsrapid inhibitor screeninggeneticsoncologymedicinal researchcancer biologyprimary human leukemias

Sweave Document From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

treatment developmentkinase pathway dependencetreatment effectsrapid inhibitor screeningcancer genomicsmolecular diagnosticscancer biologyleukemiacancer researchprimary human leukemiascancer detectionimmunologyenzyme inhibitionpharmacologygeneticsdrug resistancedrug discoveryoncologymedicinal researchmolecular medicine

Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia. Cancer Cell (2022)

Daniel BottomlyNicola LongAnna Reister SchultzStephen E. KurtzCristina E. TognonKara JohnsonMelissa AbelAnupriya AgarwalSammantha AvaylonErik BentonAurora BlucherUma BorateTheodore P. BraunJordana BrownJade BryantRussell BurkeAmy CarlosBill H. ChangHyun Jun ChoStephen ChristyCody CoblentzAaron M. CohenAmanda d’AlmeidaRachel CookAlexey DanilovKim-Hien T. DaoMichie DegninJames DibbChristopher A. EideIsabel EnglishStuart HaglerHeath HarrelsonRachel HensonHibery HoSunil K. JoshiBrian JunioAndy KaempfYoko KosakaTed LaderasMatt LawheadHyunjung LeeJessica T. LeonardChenwei LinEvan F. LindSelina Qiuying LiuPierrette LoMarc M. LoriauxSamuel LutyJulia E. MaxsonTara MaceyJacqueline MartinezJessica MinnierAndrea MonteblancoMotomi MoriQuinlan MorrowDylan NelsonJustin RamsdillAngela RofeltyAlexandra RogersKyle A. RominePeter RyabininJennifer N. SaultzDavid A. SampsonSamantha L. SavageRobert SchuffRobert SearlesRebecca L. SmithStephen E. SpurgeonTyler SweeneyRonan T. SwordsAashis ThapaKarina Thiel-KlareElie TraerJake WagnerBeth WilmotJoelle WolfGuanming WuAmy YatesHaijiao ZhangChristopher R. CogleRobert H. CollinsMichael W. DeiningerChristopher S. HouriganCraig T. JordanTara L. LinMicaela E. MartinezRachel R. PallapatiDaniel A. PollyeaAnthony D. PomicterJustin M. WattsScott J. WeirBrian J. DrukerShannon K. McWeeneyJeffrey W. Tyner

leukemiaintegrative analysismyeloid neoplasiafunctional genomicsradiation oncologysystems biologycancer researchmolecular cancercancer discoverycancer genomicsdrug responsemolecular diagnosticsoncologyoncogenesacute myeloid leukemiatumor biologycell biology

1
2
3
4
5
14
10 / page

Marc M. Loriaux, M.D., Ph.D.

Associate Professor of Pathology & Laboratory Medicine

Oregon Health & Science University

Affiliations

Biostatistics Shared Resources

Institute Of Knight Cancer

OHSU School of Medicine

Cancer Early Detection Advanced Research Center (Cedar)

Department Of Cell, Developmental And Cancer Biology

Division Of Oncological Sciences

Center Of Cancer Early Detection Advanced Research (Cedar)

Institute Of Knight Cancer

Center Of Knight Cancer

Department Of Hematopathology

Department of Medicine

Division Of Hematology/Medical Oncology

School of Dentistry

Department of Pathology and Radiology

Flow Cytometry Shared Resource

Institute Of Knight Cancer

Cancer Early Detection Advanced Research Center (Cedar)

Institute Of Knight Cancer

Division Of Oncological Sciences

Institute Of Knight Cancer

Department Of Cell, Developmental And Cancer Biology

Institute Of Knight Cancer

Division Of Hematology/Medical Oncology

Institute Of Knight Cancer Insitute

Institute Of University Knight Cancer

OHSU Knight Cancer Institute

Oregon Health & Science University

Marc M. Loriaux, M.d., Ph.d. is currently serving as a Biostatistics Shared Resources Associate Professor of Pathology & Laboratory Medicine at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Marc M. Loriaux, M.D., Ph.D.

Oregon Health & Science University

Associate Professor of Pathology & Laboratory Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Characterization of Murine Jak2 Sup V617F /Sup -Positive Myeloproliferative Disease. (2023)

Thomas G.P. BummCollin ElseaAmie S. CorbinMarc LoriauxDaniel SherbenouLisa WoodJutta DeiningerRichard T. SilverBrian J. DrukerMichael W.N. Deininger

genomicshematologygeneticsmyelopoiesismolecular biologygene characterizationcell biology

Data From the Colony-Stimulating Factor 3 Receptor T640N Mutation is Oncogenic, Sensitive to Jak Inhibition, and Mimics T618i. (2023)

carcinogenesisreceptorspharmacologygeneticsmolecular biologyoncogenestumor biology

Data From Therapeutically Targetable Alk Mutations in Leukemia. (2023)

hematological malignanciesleukemiamyeloid neoplasiacancer researchsystems biologymolecular cancermolecular diagnosticsoncogenesmolecular medicine

Supplemental Figure S1 From Therapeutically Targetable Alk Mutations in Leukemia. (2023)

Supplementary Legends for Tables 1-4 and Figures 1-7 From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

immunologyleukemiapharmacologykinase pathway dependencecancer researchsupplementary legendsrapid inhibitor screeninggeneticsoncologymedicinal researchcancer biologyprimary human leukemias

Supplementary Methods and Materials From Characterization of Murine Jak2 Sup V617F /Sup -Positive Myeloproliferative Disease. (2023)

Thomas G.P. BummCollin ElseaAmie S. CorbinMarc LoriauxDaniel SherbenouLisa WoodJutta DeiningerRichard T. SilverBrian J. DrukerMichael W.N. Deininger

myelopoiesissupplementary methodshematologycell biology

Supplementary Table 2 From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

Sweave Document From Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. (2023)

Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia. Cancer Cell (2022)

1
2
3
4
5
14
10 / page